Join Professor John Camm and Dr Stuart Connolly in their discussion of the new interim analysis of the ongoing ANNEXA-4 study: Andexanet Alfa in Factor Xa Inhibitor-Associated Acute Major Bleeding, presented at ACC.18 (67th Annual Scientific Session and Expo) in Orlando, Florida.
The ANNEXA-4 trial is an ongoing, multicenter, prospective, open-label, single-group study of andexanet in patients with acute major bleeding. The original study published results from 67 patients. This 30-minute journal club will explore the insights and impact of the recent interim results of the ANNEXA-4 trial presented at ACC 2018 as an update to the published study ‘Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors’.
View abstract access full paper
This educational activity is designed for hospitalists, haematologists, interventional cardiologists, internists/physicians, surgeons, and any other healthcare professional with an interest or role in the management of patients on anticoagulation with life-threatening bleeds.
After completing this educational activity, participants should be able to:
- Recall the percentage of anticoagulated patients (taking rivaroxaban, apixaban or enoxaparin) who achieved excellent or good haemostasis 12 hours post-andexanet alfa when they presented with a major bleed
Prof John Camm:
- Advisor for: Boehringer Ingelheim, Daiichi Sankyo
- Consultant (retained) for: Boehringer Ingelheim
- Received honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer
Dr Stuart Connolly:
- Major research grants, consulting fees and speaker fees from Sanofi-Aventis, Janssen, Pfizer, Bristol-Myers Squibb, Boehringer-Ingelheim, Boston Scientific, Abbott, Bayer Pharmaceuticals Inc, Portola Pharmaceuticals, Medtronic, Daiichi Sankyo, Servier
Staff and reviewer disclosures
PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
This independent educational activity is supported by funding from Portola Pharmaceuticals Inc. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run independently of the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.